FR10C0043I1 - Solubilisation de polysaccharides capsulaires - Google Patents

Solubilisation de polysaccharides capsulaires

Info

Publication number
FR10C0043I1
FR10C0043I1 FR10C0043C FR10C0043C FR10C0043I1 FR 10C0043 I1 FR10C0043 I1 FR 10C0043I1 FR 10C0043 C FR10C0043 C FR 10C0043C FR 10C0043 C FR10C0043 C FR 10C0043C FR 10C0043 I1 FR10C0043 I1 FR 10C0043I1
Authority
FR
France
Prior art keywords
solubilization
capsular polysaccharides
conjugate
meningococcal serogroup
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0043C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9917070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0043(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR10C0043I1 publication Critical patent/FR10C0043I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/04—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from fish or other sea animals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09F—NATURAL RESINS; FRENCH POLISH; DRYING-OILS; OIL DRYING AGENTS, i.e. SICCATIVES; TURPENTINE
    • C09F1/00—Obtaining purification, or chemical modification of natural resins, e.g. oleo-resins
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09G—POLISHING COMPOSITIONS; SKI WAXES
    • C09G1/00—Polishing compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Formation And Processing Of Food Products (AREA)
FR10C0043C 2001-06-20 2010-09-13 Solubilisation de polysaccharides capsulaires Active FR10C0043I1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0115176.0A GB0115176D0 (en) 2001-06-20 2001-06-20 Capular polysaccharide solubilisation and combination vaccines
PCT/IB2002/003191 WO2003007985A2 (en) 2001-06-20 2002-06-20 Capsular polysaccharide solubilisation and combination vaccines

Publications (1)

Publication Number Publication Date
FR10C0043I1 true FR10C0043I1 (fr) 2010-10-29

Family

ID=9917070

Family Applications (4)

Application Number Title Priority Date Filing Date
FR10C0043C Active FR10C0043I1 (fr) 2001-06-20 2010-09-13 Solubilisation de polysaccharides capsulaires
FR10C0044C Active FR10C0044I1 (fr) 2001-06-20 2010-09-13 Solubilisation de polysaccharides capsulaires
FR10C0042C Active FR10C0042I1 (fr) 2001-06-20 2010-09-13 Solubilisation de polysaccharides capsulaires
FR11C0001C Active FR11C0001I2 (fr) 2001-06-20 2011-01-14 Vaccins combines contre neisseria meningitidis

Family Applications After (3)

Application Number Title Priority Date Filing Date
FR10C0044C Active FR10C0044I1 (fr) 2001-06-20 2010-09-13 Solubilisation de polysaccharides capsulaires
FR10C0042C Active FR10C0042I1 (fr) 2001-06-20 2010-09-13 Solubilisation de polysaccharides capsulaires
FR11C0001C Active FR11C0001I2 (fr) 2001-06-20 2011-01-14 Vaccins combines contre neisseria meningitidis

Country Status (23)

Country Link
US (9) US8753651B2 (enrdf_load_stackoverflow)
EP (10) EP1741442B1 (enrdf_load_stackoverflow)
JP (4) JP5075317B2 (enrdf_load_stackoverflow)
CN (4) CN101524534B (enrdf_load_stackoverflow)
AT (3) ATE322287T1 (enrdf_load_stackoverflow)
AU (3) AU2002321716B2 (enrdf_load_stackoverflow)
BE (4) BE2010C033I2 (enrdf_load_stackoverflow)
BR (2) BR122019009186B8 (enrdf_load_stackoverflow)
CA (3) CA2730856C (enrdf_load_stackoverflow)
CY (6) CY1110820T1 (enrdf_load_stackoverflow)
DE (6) DE122010000040I1 (enrdf_load_stackoverflow)
DK (6) DK1401489T4 (enrdf_load_stackoverflow)
ES (9) ES2573259T3 (enrdf_load_stackoverflow)
FR (4) FR10C0043I1 (enrdf_load_stackoverflow)
GB (1) GB0115176D0 (enrdf_load_stackoverflow)
LU (4) LU91733I2 (enrdf_load_stackoverflow)
MX (1) MXPA03011462A (enrdf_load_stackoverflow)
NL (3) NL300458I2 (enrdf_load_stackoverflow)
NZ (2) NZ544332A (enrdf_load_stackoverflow)
PT (6) PT2277536T (enrdf_load_stackoverflow)
RU (2) RU2381814C2 (enrdf_load_stackoverflow)
TR (2) TR201808026T4 (enrdf_load_stackoverflow)
WO (1) WO2003007985A2 (enrdf_load_stackoverflow)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CN100556459C (zh) 2001-01-23 2009-11-04 安万特巴斯德公司 多价脑膜炎球菌多糖-蛋白质缀合疫苗
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1777236B8 (en) * 2002-03-26 2017-02-22 GlaxoSmithKline Biologicals SA Modified saccharides having improved stability in water for use as a medicament
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
KR20050039839A (ko) * 2002-08-02 2005-04-29 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｌｇｔｂ- 나이세리아 메닌기티디스로부터의 ｌ2 및/또는ｌ3 면역유형 리포올리고사카라이드를 포함하는 백신 조성물
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2608048T3 (es) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
PT2191844E (pt) * 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
AU2004251734B2 (en) * 2003-06-23 2010-11-04 Baxalta GmbH Vaccines against group Y neisseria meningitidis and meningococcal combinations thereof
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
DE602004032481D1 (de) * 2003-10-02 2011-06-09 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen Meningitis
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
WO2005105140A2 (en) 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) * 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
KR20070101207A (ko) * 2004-08-30 2007-10-16 사노피 파스퇴르 인크 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
KR20070095868A (ko) * 2004-09-21 2007-10-01 사노피 파스퇴르 인크 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
CA2601924A1 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
KR102564388B1 (ko) 2005-04-08 2023-08-08 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
JP2008536515A (ja) 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
GB0513071D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
ATE462444T1 (de) * 2005-06-27 2010-04-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
EP1931380A2 (en) 2005-09-01 2008-06-18 Novartis Vaccines and Diagnostics GmbH & Co. KG Multiple vaccination including serogroup c meningococcus
CA2621578C (en) * 2005-09-05 2014-07-22 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
KR101838938B1 (ko) 2006-03-17 2018-03-15 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
US20080026002A1 (en) 2006-03-22 2008-01-31 Lisa Danzig Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CN101081296B (zh) * 2006-05-29 2010-08-04 北京民海生物科技有限公司 一种b型流感嗜血杆菌荚膜多糖制备方法及其联合疫苗
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
RU2322503C1 (ru) * 2006-07-21 2008-04-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения высокоспецифичной гетерологичной антирабической сыворотки
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
MX2009003730A (es) * 2006-10-10 2009-04-22 Wyeth Corp Purificacion de polisacaridos de streptococcus pneumoniae tipo 3.
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
DK3406635T3 (da) * 2007-03-23 2022-05-30 Wyeth Llc Afkortet oprensningsmetode til fremstilling af Streptococcus Pneumoniae-kapselpolysaccharider
US8398985B2 (en) * 2007-04-23 2013-03-19 Serum Institute Of India Ltd. Antigenic polysaccharides and process for their preparation
EP2152302B1 (en) 2007-06-04 2015-10-07 GlaxoSmithKline Biologicals SA Formulation of meningitis vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
JP5501969B2 (ja) * 2007-09-11 2014-05-28 ユニバーシティ オブ グェルフ クロストリジウム・ディフィシル由来の多糖免疫原
AU2008313424B2 (en) 2007-10-19 2014-05-22 Novartis Ag Meningococcal vaccine formulations
ES2532946T3 (es) 2008-02-21 2015-04-06 Novartis Ag Polipéptidos PUfH meningocócicos
CN101724085B (zh) * 2008-10-22 2011-09-21 上海生物制品研究所 一种荚膜多糖纯化方法
EP2349520B1 (en) 2008-10-27 2016-05-25 GlaxoSmithKline Biologicals SA Purification method for carbohydrate from group a streptococcus
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
MX2011006648A (es) 2008-12-17 2011-10-14 Novartis Ag Vacunas meningococales que incluyen receptor de hemoglobina.
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
RU2603267C2 (ru) 2009-09-30 2016-11-27 Новартис Аг Конъюгация капсульных полисахаридов staphylococcus aureus типа 5 и типа 8
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
HRP20240965T1 (hr) 2010-08-23 2024-10-25 Wyeth Llc Stabilne formulacije antigena rlp2086 iz bakterije neisseria meningitidis
US9057716B2 (en) 2010-09-04 2015-06-16 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
EP3549601B1 (en) 2010-09-10 2021-02-24 Wyeth LLC Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
CU20110202A7 (es) 2011-11-02 2013-12-27 Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes
US9493517B2 (en) * 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
CN104302315B (zh) * 2012-01-30 2018-02-06 印度血清研究所私人有限公司 免疫原性组合物及其制备方法
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
KR101784644B1 (ko) 2012-03-09 2017-10-11 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
CN104487086B (zh) * 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
CN103623404B (zh) * 2012-08-28 2016-08-03 天士力制药集团股份有限公司 一种b型流感嗜血杆菌多糖结合疫苗的制备方法
MX2015002717A (es) 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
NZ708523A (en) 2012-11-21 2018-09-28 Serum Institute Of India Pvt Ltd Production of high yields of bacterial polysaccharides
CN105007935A (zh) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 用于保护免于白喉和/或破伤风的缀合物
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
BR112016000585A2 (pt) 2013-07-11 2018-03-20 Novartis Ag modificações quimioenzimáticas sítio-específicas de proteína
KR101894762B1 (ko) 2013-07-12 2018-09-05 이엠디 밀리포어 코포레이션 표적 단백질을 함유하는 샘플로부터 활성탄을 사용하여 바이러스 제거를 결정하는 방법
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
WO2015181834A2 (en) 2014-05-24 2015-12-03 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
CN104548090B (zh) * 2015-01-27 2016-11-30 中国科学院过程工程研究所 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
MX391027B (es) 2015-02-19 2025-03-21 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
CN105037579A (zh) * 2015-08-31 2015-11-11 成都欧林生物科技股份有限公司 A群脑膜炎球菌细菌荚膜粗多糖的制备工艺
EP3439704A1 (en) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogenic compositions
EP3506933A2 (en) 2016-09-02 2019-07-10 GlaxoSmithKline Biologicals SA Vaccines for neisseria gonorrhoeae
KR20190044663A (ko) 2016-09-02 2019-04-30 사노피 파스퇴르 인크 네이세리아 메닌기티디스 백신
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CA3052621A1 (en) 2017-02-03 2018-08-09 Schadeck, Eva Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US20200061542A1 (en) * 2017-02-24 2020-02-27 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US11739356B2 (en) * 2017-05-05 2023-08-29 Serum Institute Of India Private Limited Method for removal of impurities from bacterial capsular polysaccharide based preparations
RU2019140392A (ru) * 2017-05-17 2021-06-17 Мсд Веллком Траст Хиллеман Лабораторис Пвт. Лтд. Очистка бактериальных полисахаридов
MX2020002558A (es) * 2017-09-07 2020-07-13 Merck Sharp & Dohme Procesos para la formulacion de polisacaridos neumococicos para la conjugacion a una proteina transportadora.
WO2019175900A1 (en) * 2018-03-16 2019-09-19 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Purification of neisseria meningitidis polysaccharides
EP3934696A1 (en) * 2019-03-08 2022-01-12 GlaxoSmithKline Biologicals S.A. Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
CN113966234A (zh) 2019-05-10 2022-01-21 葛兰素史克生物有限公司 缀合物的产生
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
CN115721709A (zh) * 2021-08-27 2023-03-03 康希诺生物股份公司 一种肺炎球菌结合疫苗制备方法
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) * 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB207117A (en) 1923-04-05 1923-11-22 Fernand Prosper Constant Lebru Improvements in otter boards
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
US4134214A (en) 1977-08-05 1979-01-16 Merck & Co., Inc. Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
JPS59176214A (ja) * 1982-11-23 1984-10-05 ザ・ウエルカム・フアウンデ−シヨン・リミテツド 抗原性組成物
EP0109688A3 (en) 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
JPH0720878B2 (ja) * 1983-11-21 1995-03-08 ザ ウエルカム フアウンデ−シヨン リミテツド 改善された複合体、それらの製造法および該複合体を含有する製剤
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4814276A (en) * 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
US4877613A (en) 1987-08-05 1989-10-31 Biotech Connections, Inc. Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli
US4761713A (en) * 1987-11-06 1988-08-02 North American Philips Corp. Glycol based mid-volt capacitor
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0449958B9 (en) 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
US4963534A (en) 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
CA2071811C (en) * 1989-12-14 2003-11-04 Harold J. Jennings Improved meningococcal polysaccharide conjugate vaccine
SU1750689A1 (ru) * 1990-05-17 1992-07-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Способ получени полисахаридно-белковой вакцины против NeISSeRIa меNINGIтIDIS серогруппы В
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5256294A (en) * 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
ATE198834T1 (de) * 1991-03-12 2001-02-15 Us Health Konjugate bestehend aus polysaccharid und protein
WO1993004183A1 (en) 1991-08-16 1993-03-04 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DE69319728T2 (de) * 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2194236C (en) 1994-07-01 2009-02-24 Dermot Kelleher Helicobacter proteins and vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
EP0831901B2 (en) 1995-06-07 2005-12-07 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
EP1082965B1 (en) 1995-06-23 2009-06-10 GlaxoSmithKline Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
HUP9901039A2 (hu) 1996-02-01 1999-07-28 North American Vaccine, Inc. Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák
AU724862B2 (en) * 1996-02-14 2000-10-05 Merck Sharp & Dohme Corp. Polysaccharide precipitation process
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
JP4162267B2 (ja) * 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
WO1998031393A2 (en) 1997-01-21 1998-07-23 Pasteur Merieux Serums & Vaccins Polysaccharide-peptide-conjugates
DK0975790T3 (da) * 1997-01-24 2005-01-24 Berna Biotech Ag Ny fremgangsmåde til isolering af polysaccharider
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6403306B1 (en) 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
US6087328A (en) * 1997-04-24 2000-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
JP4173560B2 (ja) 1997-05-28 2008-10-29 カイロン ソチエタ ア レスポンサビリタ リミタータ アミノ酸源として酵母または大豆抽出物を含み、動物起源のタンパク質複合体を含まない培養培地
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6413520B1 (en) * 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
WO1999010372A1 (en) * 1997-08-27 1999-03-04 Chiron Corporation Molecular mimetics of meningococcal b epitopes
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
EP1854885B9 (en) 1997-11-21 2011-03-16 Merck Serono Biodevelopment Chlamydia pneumoniae outer membrane polypeptide, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100735651B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
HUP0100623A3 (en) 1997-12-23 2003-11-28 Baxter Healthcare S A Wallisel Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
CN1224708C (zh) 1998-01-14 2005-10-26 启龙股份公司 脑膜炎奈瑟氏球菌抗原
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
EP1079857B1 (en) † 1998-05-29 2006-11-29 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis b/c vaccines
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
JP2004505885A (ja) 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
US6128656A (en) * 1998-09-10 2000-10-03 Cisco Technology, Inc. System for updating selected part of configuration information stored in a memory of a network element depending on status of received state variable
EP1559795A3 (en) 1998-10-09 2005-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
IL142395A0 (en) 1998-10-16 2002-03-10 Smithkline Beecham Biolog Adjuvant systems and vaccines
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
WO2000056358A2 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against streptococcus pneumoniae capsular polysaccharides
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
EP1187629B1 (en) 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CA2838395C (en) 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
CZ20021045A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pomocný prostředek
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
ATE400296T1 (de) * 1999-12-02 2008-07-15 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
CN1201011C (zh) 2000-02-28 2005-05-11 启龙股份公司 奈瑟球菌蛋白质的异源表达
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
EP1946769B1 (en) 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
EP2166019A3 (en) 2000-07-03 2010-06-09 Novartis Vaccines and Diagnostics S.r.l. Immunisation against Chlamydia Pneumoniae
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
ATE350015T1 (de) * 2000-09-28 2007-01-15 Novartis Vaccines & Diagnostic Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
EP2277895B1 (en) 2000-10-27 2013-08-14 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
CN100556459C (zh) * 2001-01-23 2009-11-04 安万特巴斯德公司 多价脑膜炎球菌多糖-蛋白质缀合疫苗
US20030072764A1 (en) * 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
WO2003028661A2 (en) 2001-10-03 2003-04-10 Chiron Corporation Adjuvanted meningococcus compositions
EP1777236B8 (en) 2002-03-26 2017-02-22 GlaxoSmithKline Biologicals SA Modified saccharides having improved stability in water for use as a medicament
BR0310042A (pt) 2002-05-14 2005-04-05 Chiron Srl Vacinas de combinação mucosal para meningite bacteriana
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
ES2608048T3 (es) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Vacunas polipeptídicas para protección amplia contra linajes meningocócicos hipervirulentos
PT2191844E (pt) * 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
US20080026002A1 (en) * 2006-03-22 2008-01-31 Lisa Danzig Regimens for immunisation with meningococcal conjugates
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
GB2495341B (en) * 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products

Also Published As

Publication number Publication date
EP1401489B1 (en) 2006-04-05
CN101524534B (zh) 2014-05-28
US8889152B2 (en) 2014-11-18
EP2277537B1 (en) 2015-03-25
LU91778I9 (enrdf_load_stackoverflow) 2019-01-07
BE2010C031I2 (enrdf_load_stackoverflow) 2021-07-19
ES2603275T3 (es) 2017-02-24
DK2263688T3 (da) 2012-07-30
JP5380111B2 (ja) 2014-01-08
CA2450203C (en) 2011-04-19
EP2263688B2 (en) 2019-12-25
ES2387592T5 (es) 2020-07-30
LU91732I9 (enrdf_load_stackoverflow) 2019-01-07
AU2010246331A1 (en) 2010-12-09
CY1113020T1 (el) 2016-04-13
CY1110820T1 (el) 2012-01-25
EP2189165A1 (en) 2010-05-26
DE60210456T3 (de) 2013-09-05
NL300460I2 (enrdf_load_stackoverflow) 2016-12-20
CY1120499T1 (el) 2019-07-10
CN1518456A (zh) 2004-08-04
PT2277536T (pt) 2018-03-21
US9358278B2 (en) 2016-06-07
DK1741442T3 (da) 2010-08-30
FR10C0044I1 (fr) 2010-10-29
ATE556718T1 (de) 2012-05-15
RU2009108660A (ru) 2010-09-20
NL300459I2 (enrdf_load_stackoverflow) 2016-12-20
ES2573259T3 (es) 2016-06-06
LU91733I2 (fr) 2011-03-14
AU2002321716B2 (en) 2007-04-26
TR201808026T4 (tr) 2018-06-21
EP2277539A2 (en) 2011-01-26
EP2277537A2 (en) 2011-01-26
DK2189165T3 (en) 2016-06-13
CA2450203A1 (en) 2003-01-30
CA2641585A1 (en) 2003-01-30
CA2730856A1 (en) 2003-01-30
CN101524534A (zh) 2009-09-09
US9782467B2 (en) 2017-10-10
CY1117528T1 (el) 2017-04-26
EP2229954B1 (en) 2018-03-21
RU2004101284A (ru) 2005-06-27
ES2261705T5 (es) 2013-07-22
EP1401489A2 (en) 2004-03-31
NL300458I2 (enrdf_load_stackoverflow) 2016-12-20
EP1401489B2 (en) 2013-04-10
CY2011001I2 (el) 2012-01-25
BE2010C033I2 (enrdf_load_stackoverflow) 2021-07-19
EP2263688A1 (en) 2010-12-22
FR11C0001I1 (enrdf_load_stackoverflow) 2011-02-25
DK2277536T3 (en) 2018-02-26
JP2013007057A (ja) 2013-01-10
US20090117148A1 (en) 2009-05-07
AU2010246331B2 (en) 2012-11-08
ES2670219T3 (es) 2018-05-29
US8753651B2 (en) 2014-06-17
BE2010C032I2 (enrdf_load_stackoverflow) 2021-07-19
WO2003007985A3 (en) 2003-12-24
CY2011001I1 (el) 2012-01-25
US20090181049A1 (en) 2009-07-16
CY1118130T1 (el) 2017-06-28
EP2277537A3 (en) 2011-03-02
ES2539134T3 (es) 2015-06-26
FR11C0001I2 (fr) 2017-05-19
DK2263688T4 (da) 2020-03-02
DE122010000042I1 (de) 2010-12-16
PT2263688E (pt) 2012-08-02
EP2189165B1 (en) 2016-03-09
EP2216044B1 (en) 2018-03-21
CA2641585C (en) 2011-02-08
NZ529881A (en) 2006-03-31
EP2229954A1 (en) 2010-09-22
EP1741442B1 (en) 2010-07-21
JP2009114211A (ja) 2009-05-28
LU91734I9 (enrdf_load_stackoverflow) 2019-01-07
PT2184071T (pt) 2016-11-14
CN100482273C (zh) 2009-04-29
US9782466B2 (en) 2017-10-10
ES2347458T3 (es) 2010-10-29
DK1401489T4 (da) 2013-07-01
ATE322287T1 (de) 2006-04-15
EP1741442A2 (en) 2007-01-10
PT1401489E (pt) 2006-08-31
JP5220658B2 (ja) 2013-06-26
BR122019009186B8 (pt) 2021-07-27
DE122011000003I1 (de) 2011-05-05
DE122010000040I1 (de) 2010-12-16
PT2277537E (pt) 2015-06-30
US20050106181A1 (en) 2005-05-19
EP2277536A2 (en) 2011-01-26
BE2011C001I2 (enrdf_load_stackoverflow) 2021-07-19
BRPI0210590B1 (pt) 2019-10-01
CN101524533A (zh) 2009-09-09
RU2381814C2 (ru) 2010-02-20
US20090182128A1 (en) 2009-07-16
EP2277536B1 (en) 2018-01-31
ES2387592T3 (es) 2012-09-26
PT1741442E (pt) 2010-10-28
DE60210456D1 (de) 2006-05-18
US20090130140A1 (en) 2009-05-21
CN101524535B (zh) 2015-12-16
ES2670196T3 (es) 2018-05-29
DE60210456T2 (de) 2006-11-16
AU2007203442B2 (en) 2010-08-26
EP2216044A1 (en) 2010-08-11
DK1401489T3 (da) 2006-07-03
WO2003007985A2 (en) 2003-01-30
EP2184071B1 (en) 2016-08-31
EP2277539A3 (en) 2011-03-02
BR0210590A (pt) 2004-11-09
CA2730856C (en) 2015-07-28
BR122019009186B1 (pt) 2020-05-26
US20090181053A1 (en) 2009-07-16
CN101524535A (zh) 2009-09-09
BRPI0210590B8 (pt) 2021-05-25
EP2263688B1 (en) 2012-05-09
US20090130147A1 (en) 2009-05-21
EP1741442A3 (en) 2007-01-17
DK2184071T3 (en) 2016-11-07
RU2528066C2 (ru) 2014-09-10
ATE474594T1 (de) 2010-08-15
AU2007203442A1 (en) 2007-08-16
US9452207B2 (en) 2016-09-27
DE122010000041I1 (de) 2010-12-16
EP2184071A1 (en) 2010-05-12
DE60237123D1 (de) 2010-09-02
LU91733I9 (enrdf_load_stackoverflow) 2019-01-07
US8852606B2 (en) 2014-10-07
NZ544332A (en) 2006-10-27
US20090182129A1 (en) 2009-07-16
JP2004536859A (ja) 2004-12-09
FR10C0042I1 (fr) 2010-10-29
LU91732I2 (fr) 2011-03-14
JP2009114210A (ja) 2009-05-28
MXPA03011462A (es) 2005-04-19
TR201808055T4 (tr) 2018-06-21
LU91734I2 (fr) 2011-03-14
ES2261705T3 (es) 2006-11-16
JP5075317B2 (ja) 2012-11-21
US10716841B2 (en) 2020-07-21
US20170043004A1 (en) 2017-02-16
GB0115176D0 (en) 2001-08-15
EP2277536A3 (en) 2011-02-23
LU91778I2 (fr) 2011-03-14
ES2662015T3 (es) 2018-04-05

Similar Documents

Publication Publication Date Title
FR10C0042I1 (fr) Solubilisation de polysaccharides capsulaires
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
NZ512011A (en) Improved saponin adjuvant compositions and methods relating thereto
WO2003051392A3 (en) Streptococcus pneumoniae vaccine
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
AU2002353417A1 (en) Adjuvanted antigenic meningococcal compositions
WO2003051288A3 (en) Mycobacterial vaccine
WO2002010343A3 (en) Temperature-sensitive live vaccine for mycoplasma hyopneumoniae
WO2000050073A3 (en) Caulobacter lps immunoadjuvant